Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

Small Study Hints at Mechanism for COVID-Related MI and Stroke

L.A. McKeown

October 02, 2023

News Daily News

Half of American Indian and Alaska Native Seniors Have CVD: Medicare Analysis

L.A. McKeown

September 25, 2023

News Daily News

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

Michael O'Riordan

October 28, 2021

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Daily News

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Todd Neale

June 22, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Yael L. Maxwell

June 05, 2015

News Daily News

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

May 27, 2011

Advertisement

Risk Factors Present in Nearly All Patients Who Develop CVD

Small Study Hints at Mechanism for COVID-Related MI and Stroke

Half of American Indian and Alaska Native Seniors Have CVD: Medicare Analysis

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Recurrent Events Common Among Young Patients With CAD

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content